SERUM 25 (OH) VITAMIN D AND ITS ROLE IN SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE
Abstract
Background & Objective: Chronic Kidney Disease (CKD) is emerging as an important public health problem across the world. In severe cases, the disease progresses towards end stage renal disease (ESRD) which is associated with several complications. In recent years, 25 (OH) Vitamin D has been identified as a risk factor for ESRD. Vitamin D plays a vital role in regulating parathyroid hormone (PTH) synthesis and release. Decreased Vitamin D levels are identified as a risk factor for secondary hyperparathyroidism (SHPT) which is one of the major complications of CKD and is associated with renal osteodystrophy. The present study was planned to assess the status of 25 (OH) Vitamin D and its role in secondary hyperparathyroidism in patients with CKD. Materials and Methods: The study was conducted on 50 diagnosed cases of CKD (stage 4 and 5), age < 60 years. Age and sex matched healthy subjects (n = 50) constituted the control group. Serum 25(OH) Vitamin D and iPTH were estimated for all the enrolled subjects. BMI and eGFR were also calculated. All variables were compared among the control and diseased group. Results: Vitamin D levels were significantly low in the CKD group as compared to the control group (p<0.001). 72% of the total CKD patients were deficient in Vitamin D levels. Serum iPTH was significantly higher in the CKD patients (p = 0.000). A significant negative correlation was observed between iPTH and Vitamin D (r = -0.614). Conclusion: The study suggests that patients of CKD are at high risk of Vitamin D deficiency. Vitamin D deficiency has a strong association with the pathogenesis of SHPT.
KEYWORDS: Chronic Kidney Disease; Vitamin D; Parathyroid hormone; Secondary Hyperparathyroidism; End Stage Renal Disease.
Downloads
Downloads
Published
Issue
Section
License
The journal allows the author(s) to hold the copyright without restrictions and will retain publishing rights without restrictions.
The submitted papers are assumed to contain no proprietary material unprotected by patent or patent application; responsibility for technical content and for protection of proprietary material rests solely with the author(s) and their organizations and is not the responsibility of the journal. The main (first/corresponding) author is responsible for ensuring that the article has been seen and approved by all the other authors. It is the responsibility of the author to obtain all necessary copyright release permissions for the use of any copyrighted materials in the manuscript prior to the submission.
What are my rights as an author?
It is important to check the policy for the journal to which you are submitting or publishing to establish your rights as
Author. Journal's standard policies allow the following re-use rights:
- The journal allows the author(s) to hold the copyright without restrictions.
- The journal allows the author(s) to obtain publishing rights without restrictions.
- You may do whatever you wish with the version of the article you submitted to the journal.
- Once the article has been accepted for publication, you may post the accepted version of the article on your own personal website, your department's website or the repository of your institution without any restrictions.
- You may not post the accepted version of the article in any repository other than those listed above (i.e. you may not deposit in the repository of another institution or a subject-matter repository) until 12 months after publication of the article in the journal.
- You may use the published article for your own teaching needs or to supply on an individual basis to research colleagues, provided that such supply is not for commercial purposes.